


Supplementary Figure 1


A

Phase 1b: Safety and Toxicity



B

Immune Response Study



*Non-hematologic DLT

**560 mg/day unless 420 or 280 mg/day determined to be MTD

***Ibrutinib to start 5-7 days after post-run in biopsy